Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.

Rodriguez-Porcel, Federico; Wyman-Chick, Kathryn A; Abdelnour Ruiz, Carla; Toledo, Jon B; Ferreira, Daniel; Urwyler, Prabitha; Weil, Rimona S; Kane, Joseph; Pilotto, Andrea; Rongve, Arvid; Boeve, Bradley; Taylor, John-Paul; McKeith, Ian; Aarsland, Dag; Lewis, Simon J G (2022). Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Translational neurodegeneration, 11(1), p. 24. BioMed Central 10.1186/s40035-022-00299-w

Preview

Text s40035-022-00299-w.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (871kB) | Preview

The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials.

Interest & Impact

Downloads

64 since deposited on 03 May 2022
37 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item